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hIt has long been known that Down syndrome (DS) children
have an increased risk of leukaemia. On the other hand,
reports of solid malignancies are rare. Large population-based
and/or tumour registries have shown that solid tumours occur
signiﬁcantly less frequently in DS children and adults in
comparison with individuals without trisomy 21. Among
2814 individuals from different age groups with DS registered
in a Danish study, only 24 cases of solid tumours were
identiﬁed, whereas 47.7% cases would have been expected
[1]. A British registry of 11,000 childhood solid tumour cases
identiﬁed only seven tumours in DS children [lymphoma (3),
teratoma (1), glioma (2), and ﬁbrosarcoma (1)] [2]. This is true
also in adult tumours. Among 1278 women with DS registered
in the Danish Cytogenetic and Danish Cancer Registries, no
cases of breast cancer were identiﬁed, while at least seven cases
would have been expected [1].
The protective effect of the extra copy of chromosome
against the development of certain malignancies was docu-
mented in neuroblastoma: The S-100b protein (encoded by a
chromosome 21-localised gene) is higher in DS patients which
may contribute to its lower incidence. This protein can inhibit
the growth and induce death of human and murine neuroblas-
toma cell lines [3,4].
The presence of an extra copy of chromosome 21 also
protects against the progression of tumours where several
genes are involved, all mapped to chromosome 21: COL18A1
gene, encoding endostatin which is a soluble 20 kd cleavage
product of collagen XVIII. It is a potent angiogenesis inhibitor
for many different types of solid tissue tumours in both human
and animal models [5]. Zorick et al. found that endostatin is
signiﬁcantly higher in DS patients and suggested that
individuals with serum endostatin levels higher than 20 ng/ml
might be less prone to the development of solid tumours than
those with lower levels and therefore, it will be important to
evaluate the use of endostatin levels as a predictive test [6].
Endostatin was also found to inhibit tumour lymphangio-
genesis by decreasing the vascular endothelial growth factor
C (VEGF-C) levels in tumours, apparently via inhibition of
mast cell migration and adhesion [7].eer review under responsibility of Ain Shams University.
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for cancer therapy in humans. A phase III clinical trial was
carried out on 493 histology or cytology conﬁrmed stage IIIB
and IV none small cell lung patients. Patients were treated with
Endostar, a recombinant endostatin product in combination
with the standard chemotherapeutic regimen. This addition
resulted in signiﬁcant and clinically meaningful improvement
in response rate, median time to progression, and clinical
beneﬁt rate compared with the chemotherapeutic regimen
alone [8].
The extra copy of chromosome 21 protects also against
tumour progression through another two genes:Down syndrome
critical region 1 (DSCR-1, also known as RCAN1) gene and
dual-speciﬁcity tyrosine-phosphorylated and -regulated kinase
1A (Dyrk1a) which play a crucial role in inhibiting the growth
of new blood vessels [6,9]. These two genes encode proteins
that disrupt the calcineurin pathway, which is involved in
angiogenesis. Ryeom and Folkman found that DSCR1 protein
levels increased in both the tissues of people with DS and in the
mouse model of DS. The growth of tumours was also
suppressed, and the density of microvessels was statistically
signiﬁcantly lower in the DS mice than in the diploid control
mice [10].
Recently, trisomy of the DSCR1 gene was found to
suppress early progression of pancreatic intraepithelial
neoplasia driven by oncogenic K-ras [11] and is sufﬁcient to
suppress tumour angiogenesis during spontaneous lung
tumourigenesis [12].
The DYRK1 gene was suggested to act in concert with
DSCR1 to suppress tumour angiogenesis by further attenuat-
ing VEGF-calcineurin-NFAT signalling in endothelial cells
[13].
Other genes involved in inhibition of tumour progression
were discovered by Reynolds et al., who identiﬁed two putative
anti-angiogenic genes [14]: ADAMTS1 which is a protease
signiﬁcantly blocks vascular endothelial growth factor receptor
2 (VEGFR2) phosphorylation with consequent suppression
of endothelial cell proliferation [15] and ERG which is a
transcription factor implicated in endothelial tube formation
and angiogenesis [16].
They also identiﬁed novel endothelial cell-speciﬁc genes,
never shown before to be involved in angiogenesis (JAM-B
and PTTG1IP) that, when over-expressed, are responsible for
the inhibition of angiogenic responses to VEGF [14].in Shams University.
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served in their lower incidence of diabetic retinopathy. The ex-
tra amount of endostatin protects individuals with DS from
this diabetes complication through the same mechanism of
reducing angiogenesis [10]. Endostar, has been considered as
one of the most valuable anti-angiogenic agents as it inhibits
both the proliferation of the choroid-retinal endothelial cells
through limiting the progression of the cell cycle and their
migration. Furthermore, it induces the expression of the pig-
ment epithelial-derived factor (PEDF) and suppresses the
expression of the vascular endothelial growth factor (VEGF)
and the ﬁbroblast growth factor (FGF). Endostar also reduces
the expression of the inﬂammatory mediator tumour necrosis
factor-alpha (TNF-alpha), matrix metalloproteinases (MMPs)
and vascular cell adhesion molecule-1 (VCAM-1). These ﬁnd-
ings reveal an integrated role of Endostar in the programme of
retinal vascular control and highlight its signiﬁcant potential
for broad clinical application [17].
High levels of endostatatins may also act as antiinﬂamma-
tory. Recombinant human endostatin was effective in reducing
proliferation and inducing apoptosis of synovial ﬁbroblasts
and in rheumatoid arthritis in rats. These ﬁndings highlight
the potential use of endostatin as a treatment for rheumatoid
arthritis [18].
As we should expect, individuals with DS have an 80% risk
reduction of vascular anomalies. This protective effect is most
likely because of increased gene product resulting from an ex-
tra copy of chromosome 21. Potential candidate genes on this
chromosome include VEGF inhibitors COL18A1, DSCR1, or
DYRK1A. Because VEGF is involved in the pathogenesis of
both haemangioma and vascular malformations, increased
gene product from these genes [19].
Interesting enough, trisomy 21 has an extra neuroprotective
mechanism through over-expression of DSCR1 which im-
proves the outcome following stroke in mice. Mechanisms
underlying this protection may involve calcineurin-indepen-
dent, anti-inﬂammatory and anti-apoptotic effects mediated
by DSCR1 in neurons [20].
Conclusions
As much grief as the family has when they receive the news of
having a child with DS, the blessing effect of the extra copy of
chromosome 21 (through its role in reducing the incidence and
progression of solid tumour, the anti inﬂammatory effect and
the stroke neuro-protection) endorses the human believe that
in every tragedy there is a hidden rainbow. There may come
a time when scientists induce trisomy 21 in cells as a form of
anti-inﬂammatory or anti cancer therapy.
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